Skip to main content
. 2021 Jun 15;131(12):e146353. doi: 10.1172/JCI146353

Figure 3. Tirzepatide enhances insulin sensitivity in a weight-dependent and -independent manner.

Figure 3

Obese insulin-resistant mice dosed once daily with vehicle, semaglutide, or tirzepatide for 14 days (n = 14–15 per group). (A) Daily body weight and food intake. Following 14 days of treatment, insulin sensitivity was assessed via a hyperinsulinemic-euglycemic clamp. (B) Average glucose infusion rates (GIR) throughout and during the final 30 minutes of the clamp. (C) Average GIR fold change when comparing TZP to that of weight-matched groups during the final 30 minutes of the clamp. (D) Endogenous glucose production (EGP). Insulin-stimulated glucose disposal in (E–G) skeletal muscle, (H and I) white adipose tissue (epididymal and inguinal adipose tissue [eWAT and iWAT]), and (J) brown adipose tissue (interscapular brown adipose tissue [iBAT]). Data are presented as mean ± SEM. *P < 0.05 compared with vehicle, #P < 0.05 compared with semaglutide, and §P < 0.05 compared with pair fed. Statistical analyses performed included 1-way ANOVA or Kruskal-Wallis test followed by Bonferroni multiple comparisons test, where appropriate.